Topic: Reblozyl (luspatercept–aamt)

Bristol-Myers Squibb

32. Reblozyl

Bristol-Myers and Acceleron are also seeking approval in myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow don’t fully develop and become healthy blood cells. If Reblozyl nabs a second nod, analysts figure it could hit $2 billion in yearly sales.